c-KIT mutation analysis in tumors of hematopoietic tissue
c-KIT mutation analysis in tumors of hematopoietic tissue-994
c-KIT mutation, liquid tumor
D816V
Lavender (EDTA), 10mL
Whole blood
Dk green Sodium heparin (Na hep), no gel
Bone Marrow
Dk green Sodium heparin (Na hep), no gel
Lavender (EDTA), 4mL
Ambient (preferred)
If specimen is stored prior to transport, store at 2 - 8°C.
- Specimen does not meet all of the criteria for sample type, container, minimum volume, collection and storage
- Frozen whole blood or marrow
- Leaking tube
- Clotted blood or marrow
- Grossly hemolyzed or otherwise visibly degraded specimen
- Specimen suspected of being contaminated by another specimen
- Specimen contains specific foreign material
Polymerase chain reaction (PCR) and DNA sequencing
An interpretive report will be provided
c-KIT is a proto-oncogene that encodes a type III transmembrane tyrosine kinase. c-KIT and its ligand stem cell factor have a key role in survival, proliferation, differentiation, and functional activation of hematopoietic progenitor cells. c-KIT mutations are reported in nearly all systemic mastocytosis, 20% to 40% core-binding factor (CBF) acute myeloid leukemia (AML), and approximately 20% high-grade myelodysplastic syndrome (MDS) and MDS-derived AML. c-KIT mutation in AML confers increased risk of relapse and decreased overall survival. Tyrosine kinase inhibitor, such as imatinib, has been evaluated to treat systemic mastocytosis and c-KIT-positive AML and MDS, and it was found effective as a single reagent or combination therapy.
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medical billing request form along with the sample.
- Complete and submit the form to notify us of the need for Allina Health Laboratory to bill insurance for Molecular testing performed
- All information requested is required in order for your request to be completed